CCCC Q4 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+112.8% YoY

Gross Profit

$9M83.6% margin

Operating Income

-$12M-112.7% margin

Net Income

-$20M-186.0% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-1.9%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$359M

Total Liabilities

$102M

Stockholders' Equity

$257M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$5M	+112.8%
Gross Profit	$9M	$3M	+170.0%
Operating Income	-$12M	-$38M	+67.1%
Net Income	-$20M	-$35M	+40.7%